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Abstract
Purpose The constellation of advanced cardiac life sup-
port (ACLS) events, such as gas embolism, local anesthetic
overdose, and spinal bradycardia, in the perioperative set-
tingdiffersfromeventsinthepre-hospitalarena.Asaresult,
modiﬁcation of traditional ACLS protocols allows for more
speciﬁc etiology-based resuscitation.
Principal ﬁndings Perioperative arrests are both
uncommon and heterogeneous and have not been described
or studied to the same extent as cardiac arrest in the
community. These crises are usually witnessed, frequently
anticipated, and involve a rescuer physician with knowl-
edge of the patient’s comorbidities and coexisting
anesthetic or surgically related pathophysiology. When the
health care provider identiﬁes the probable cause of arrest,
the practitioner has the ability to initiate medical man-
agement rapidly.
Conclusions Recommendations for management must be
predicated on expert opinion and physiological under-
standing rather than on the standards currently being used
in the generation of ACLS protocols in the community.
Adapting ACLS algorithms and considering the differential
diagnoses of these perioperative events may prevent car-
diac arrest.
Re ´sume ´
Objectif Le grand ensemble d’e ´ve ´nements lie ´sa ` la
re ´animation cardiaque avance ´e (ACLS) tels que les
embolies gazeuses, les surdosages d’anesthe ´siques locaux
et la bradycardie sinusale dans un contexte pe ´riope ´ratoire
est diffe ´rent des e ´ve ´nements que l’on observe a ` l’exte ´rieur
de l’hopital. En conse ´quence, une modiﬁcation des
protocoles traditionnels d’ACLS permet une re ´animation
plus spe ´ciﬁque, en fonction de l’e ´tiologie.
Constatations principales Les arre ˆts cardiaques en
pe ´riode pe ´riope ´ratoire sont a ` la fois rares et he ´te ´roge `nes;
ils n’ont pas e ´te ´ de ´crits ou e ´tudie ´s avec la me ˆme ampleur
que les arre ˆts cardiaques survenant hors de l’ho ˆpital. Ces
crises sont habituellement ve ´cues en direct, souvent
anticipe ´es et impliquent l’intervention d’un me ´decin
connaissant les comorbidite ´s du patient ainsi que la
physiopathologie en rapport avec l’intervention et les
anesthe ´siques utilise ´s. Lorsque le professionnel de la sante ´
identiﬁe la cause probable de l’arre ˆt cardiaque, le
praticien a la possibilite ´ d’entreprendre rapidement une
prise en charge me ´dicale.
Conclusions Des recommandations pour la prise en
charge doivent e ˆtre fonde ´es sur les avis d’experts et sur la
compre ´hension de la physiologie pluto ˆt que sur des normes
actuellement utilise ´es pour la cre ´ation de protocoles
d’ACLS hors du milieu hospitalier. L’adaptation des
algorithmes d’ACLS et la prise en compte des diagnostics
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Part 1
Introduction
Advanced cardiac life support (ACLS) was originally
developed as an extension of basic life support with a focus
on the resuscitation of individuals found unresponsive in
the community by providing chest compression and
respiratory support. These clinical interventions were later
expanded to immediate care in the emergency department
and were then exported to unresponsive patients elsewhere
in the hospital.
The initiation of cardiopulmonary resuscitation (CPR) is
predicated on the discovery of an unresponsive patient who
does not have a pulse.
1 Advanced cardiac life support is
rhythm oriented and speciﬁc to sudden manifestations of
cardiac and respiratory diseases outside of the hospital.
This approach presumes that effective chest compression,
adequate ventilation, and electrical and pharmacological
management of a pulseless cardiac rhythm will result in the
return of spontaneous circulation (ROSC).
2,3
Cardiac arrest during anesthesia is distinct from cardiac
arrest in other settings because it is usually witnessed and
frequently anticipated. Compared with other settings, the
response may be both more timely and focused. In the
perioperative setting, a patient with a known medical his-
tory typically deteriorates into crisis over a period of
minutes or hours under circumstances wholly dissimilar to
other in-hospital or out-of-hospital scenarios. Conse-
quently, aggressive measures can be taken to support the
patient’s physiology and avoid or delay the need for ACLS.
Additionally, patients in the perioperative period have a
different pathophysiologic milieu. For example, hypovol-
emia is far more common than a transmural myocardial
infarction from plaque rupture. Similarly, prolonged hyp-
oxemia and hypercarbia resulting from the management of
unpredictable difﬁcult airways is a well-recognized cause
of cardiac arrest in the operating room (OR).
4-7 Brady-
cardiac arrest in the OR is caused or precipitated by
vagotonic analgesics, physical manipulations that increase
vagal tone, and sympatholysis from anesthetic agents and
regional/neuraxial anesthetic techniques.
8,9
A large prospective and retrospective case analysis
study of all perioperative cardiac arrests occurring during a
ten-year period (1989-1999) in a single teaching institution
showed an overall incidence of cardiac arrest from all
causes of 19.7 per 10,000 anesthetics and a risk of death
related to anesthesia-attributable perioperative cardiac
arrest of 0.55 per 10,000 anesthetics.
4 In a review of car-
diac arrests associated with anesthesia, the most common
electrocardiogram (ECG) rhythms at the time of arrest
were bradycardia (23%), asystole (22%), tachydysrhythmia
(including ventricular tachycardia and ventricular ﬁbrilla-
tion) (14%), and normal (7%). Remarkably, in 33% of the
cases, the heart rhythm was not fully assessed or docu-
mented.
10 The introduction of worldwide safety standards
and improved understanding of the physiologic impact of
anesthetic agents is consistent with recent epidemiological
data suggesting an improvement of anesthesia-related
mortality risk in the United States and abroad, with
the highest death rate found in very elderly patients
(C 85 yr).
11
Although the cause of circulatory arrest is usually
unknown in patients found in the ﬁeld, there is a relatively
short list of probable causes of circulatory collapse during
the perioperative period.
4-6,8,9 This certainty produces more
focused and etiology-based resuscitation efforts, which
frequently do not follow the more generic algorithms of the
ACLS guidelines.
Anesthesia and cardiac arrest
Common situations associated with perioperative cardiac
arrest are listed in Table 1. A comprehensive list of trends
in anesthesia-related deaths is available from an analysis of
insurance-based claims covering 13,000 anesthesiologists
in North America.
7 Herein, several common scenarios are
analyzed in detail.
Neuraxial anesthesia
Epidemiology reviews of cardiac arrest during neuraxial
anesthesia suggest an incidence of 1.3-18 per 10,000
patients.
9,12-15 A recent review of cardiac arrests during
neuraxial anesthesia reports a prevalence of 1.8 cardiac
arrests per 10,000 patients, with more arrests occurring in
patients receiving spinal anesthesia vs all the other tech-
niques (2.9 vs 0.9 per 10,000 patients, respectively;
P = 0.041). In this review, cardiac arrest during neuraxial
anesthesia was associated with a greater likelihood of
survival compared with cardiac arrest during general
anesthesia.
9
Although there is a substantial amount of basic science
and clinical interest in the effects of high spinal anesthesia
on the sympathetic innervation of the heart and circula-
tion,
16-22 the pathophysiology of cardiac arrest remains
unclear. Various hypotheses have been proposed, invoking
factors such as unrecognized respiratory depression,
excessive sedation concurrent with a high block, unde-
rappreciation of both the direct and indirect circulatory
consequences of a high spinal anesthetic, and failure to
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123rescue with airway management and drugs.
8,9,23-26 Hyp-
oxemia from hypoventilation is an unlikely etiology
because there are case reports documenting adequate
oxygen saturation in these patients. Neuraxial cardiac
arrests are most likely precipitated by the combination of
autonomic imbalance with enhanced vagal tone and an
acute decrease in preload from venodilatation.
8,9
During the perioperative period, cardiac arrest in asso-
ciation with neuraxial anesthesia is difﬁcult to predict
8,9,27
and may occur more than 40 min after injection.
9,12 Pro-
posed risk factors for bradycardia or cardiac arrest during
spinal anesthesia include American Society of Anesthesi-
ologists (ASA) physical status I vs ASA physical status III
or IV, age\50 yr, heart rate\60 beats min
-1, prolonged
P-R interval, use of beta-blocking drugs, and a sensory
level above T6.
8 In a review of neuraxial cardiac arrests,
almost 50% of cardiac arrests were associated with recur-
rent speciﬁc surgical events (cementing of joint
components, spermatic cord manipulation, manipulation of
a broken femur, blood loss, and rupture of amniotic
membranes).
9 Avoiding anesthesia during surgical manip-
ulation is not feasible, making it difﬁcult to determine the
contribution of anesthesia and manipulation in isolation to
the development of neuroaxial cardiac arrest. The patho-
physiology of this phenomenon is unclear, and the
selection of vasoactive drugs during neuraxial anesthesia is
controversial.
28 A proposed treatment protocol is outlined
in Table 2.
Local anesthetics
Although the risk of local anesthetic toxicity is difﬁcult to
predict, the risk for toxicity increases with dose and site of
injection.
29 In general, local anesthetics depress the heart in
a dose-dependent fashion and can cause bradycardia,
asystole, decreased contractility, and hypotension.
29-31
Other determinant factors of anesthetic blood level and
systemic toxicity are the site of injection and the rate
of absorption. Direct intravascular injection of a local
anesthetic typically produces an immediate toxic
effect, whereas toxicity from absorption over time from
Table 1 Common situations associated with perioperative cardiac
arrest
Anesthetic
Intravenous anesthetic overdose
Inhalation anesthetic overdose
Neuraxial block with high level sympathectomy
Local anesthetic systemic toxicity
Malignant hyperthermia
Drug administration errors
Respiratory
Hypoxemia
Auto-PEEP
Acute bronchospasm
Cardiovascular
Vasovagal reﬂex
Hypovolemic and/or hemorrhagic shock
Surgical maneuvers associated with reduced organ blood ﬂow
Gas embolism
Acute electrolyte imbalance (high K, low Ca
??)
Increased intra-abdominal pressure
Transfusion reaction
Anaphylactic reaction
Tension pneumothorax
Acute coronary syndrome
Pulmonary thromboembolism
Severe pulmonary hypertension
Pacemaker failure
Prolonged Q-T syndrome
Oculocardiac reﬂexes
Electroconvulsive therapy
PEEP = positive end-expiratory pressure
Table 2 Treatment of cardiac arrest associated with neuraxial anesthesia
Pre-Arrest
• Discontinue anesthetic or sedation infusion
• Immediate tracheal intubation and ventilation with 100% oxygen
• Treat bradycardia with 1 mg atropine
• Treat bradycardia with severe hypotension with at least 1 mg epinephrine iv
• Consider transcutaneous or intravenous pacemakers for all symptomatic bradycardic rhythms with pulse
• Consider chest compressions at a rate of 100 compressions min
-1 if above measures are ineffective
Cardiac Arrest
• Immediate CPR as indicated (no carotid pulse, absence of ECG rhythm, loss of arterial catheter, and pulse oximeter signal)
• Epinephrine 1 mg iv; consider alternative approach to drug therapy, i.e., escalating doses or reducing epinephrine time interval to every
1–2 min
• Consider concurrent treatment with vasopressin 40 U iv
CPR = cardiopulmonary resuscitation; ECG = echocardiogram
588 V. K. Moitra et al.
123well-vascularized peripheral tissue, such as the pleural
space, may present in a delayed fashion.
29
Bupivacaine, the local anesthetic agent most often
associated with cardiac arrest, is a potent and well-descri-
bed myocardial depressant.
30-34 Fortunately, most awake
patients who are developing systemic toxicity manifest
early neurological symptoms that may suggest impending
myocardial dysfunction. In some unfortunate patients,
however, these changes presage cardiac arrest.
Manifestations of local anesthetic toxicity include
ringing in the ears or buzzing in the ears, metallic taste or
perioral tingling, dysphasia, orthostatic hypotension, con-
fusion, premature ventricular contractions, wide QRS
complex ECG (which can subsequently deteriorate into
pulseless electrical activity [PEA] or asystole [bupiva-
caine]), sinus bradycardia or atrioventricular block
(lidocaine and etidocaine), and decreased myocardial
contractility. A treatment protocol for this complication is
given in Table 3.
35-41
Anaphylaxis
Anaphylaxis is a rare but important cause of circulatory
collapse in the perioperative period.
27,42 The reported
incidence of anaphylaxis is from one in 10,000 to one in
20,000 anesthetics, with 3-10% of those cases being life-
threatening.
43-45 Although there is a wide range of minor
allergic reactions, hypotension, tachycardia, broncho-
spasm, and vasoplegic shock may follow when the
offending agent is administered as a rapid intravenous
bolus - the most common route of drug administration
during anesthesia.
46 The preponderance of anaphylaxis in
perioperative patients is caused by a small number of
drugs, particularly neuromuscular blocking agents.
43,47
Common causes of anaphylactic shock include nonde-
polarizing neuromuscular blockers, beta-lactam antibiotics,
latex exposure, and intravenous contrast.
The focus for management of a patient with anaphylaxis
is on interrupting the reaction and supporting the patient
(Table 4).
48,49 If feasible, surgery should be interrupted,
and the patient should be immediately supported with
intravenous ﬂuids and vasopressors.
34 Early consideration
should be given to securing the airway if the patient
experiences inspiratory stridor or develops facial and lip
swelling. It is imperative to remember that epinephrine
administered to patients with anaphylaxis is intended to
both interrupt the reaction and support circulation.
50 Thus,
it should be given at an initial bolus dose and followed by
an epinephrine infusion titrated to maintain a systolic blood
pressure of at least 90 mmHg. Adjunct therapies, such as
arginine vasopressin, corticosteroids, and H1 and H2
receptor antagonists, may be considered and are listed in
Table 4.
42,48
Gas embolism
Gas embolism is an important cause of circulatory crisis
and cardiac arrest in perioperative patients. As the number
of procedures using minimally invasive techniques
involving gas insufﬂation increases, the frequency of
intraoperative gas embolisms will likely increase. The risk
for a venous air embolism increases when the surgical ﬁeld
is above the right atrium, particularly in patients with low
central venous pressure (CVP). The focus of hemodynamic
support is on improving right ventricular (RV) function
51
(Table 5).
Table 3 Treatment of local anesthetic toxicity
Pre-Arrest
• Stop the administration of local anesthetic
• Immediate tracheal intubation and ventilation with 100% oxygen
• Consider transcutaneous or intravenous pacemakers for all
symptomatic bradycardic rhythms with pulse
• If the diagnosis of local anesthetic toxicity is strongly suspected, the
use of epinephrine should be avoided as it can worsen outcome
35,36
• Consider chest compressions at rate of 100 compressions min
-1 if
above measures are ineffective
• 20% intralipid iv, 1.5 mL kg
-1 iv load, then 0.25 mL kg
-1 hr
-1
37,38 (the efﬁcacy of this therapy is still debated and under
investigation, and it should complement and not substitute the
immediate use of catecholamines
39,40)
• Seizures should be treated with benzodiazepines. Small doses of
propofol or thiopental may be used if benzodiazepines are not
immediately available
41
Cardiac Arrest
• Immediate CPR as indicated (no carotid pulse, ECG, arterial
catheter, and pulse oximeter signal)
• If the diagnosis of local anesthetic toxicity is strongly suspected,
small doses of epinephrine 10-100 lg are preferable to higher
doses
41
• Vasopressin is not recommended
41
• Sodium bicarbonate to maintain a pH[7.25 in patients without
immediate ROSC after CPR and drug therapy
• If ROSC does not occur following the ﬁrst bolus of lipid emulsion, a
second bolus followed by a doubling of the rate of infusion is
appropriate
41
• Consider therapy with H1 and H2 blockers
• Amiodarone is the drug of choice for ventricular arrhythmias.
Lidocaine should be avoided
41
• Most important, continue CPR for a prolonged period (we suggest at
least 60 minutes) as very good neurologic recovery has been
reported in patients after very prolonged cardiac arrests from local
anesthetic overdoses
• ECMO may be appropriate in circumstances where the diagnosis is
certain, where ECMO is available in a timely fashion, and where
there is no ROSC after a second bolus of lipid emulsion
41
CPR = cardiopulmonary resuscitation; ECG = electrocardiogram;
ROSC = return of spontaneous circulation; ECMO = extracorporeal
membrane oxygenation
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123Common causes of gas embolism include laparoscopy,
endobronchial laser procedures, central venous catheteri-
zation or catheter removal, hysteroscopy, pressurized
wound irrigation, prone spinal surgery, posterior fossa
surgery in the sitting position, and pressurized ﬂuid
infusion.
Massive gas embolisms have been characterized by
breathlessness, continuous coughing, arrhythmias, myo-
cardial ischemia, acute hypotension with loss of end-tidal
carbon dioxide, and cardiac arrest.
51
Acute hyperkalemia
Hyperkalemia can be an elusive but important cause of
cardiac arrest in perioperative patients regardless of pre-
existing kidney injury. It is important for practitioners to
appreciate that many patients who sustain a hyperkalemic
cardiac arrest do not appear to undergo the orderly dete-
rioration of cardiac rhythm (peaked T waves followed by a
widened QRS complex and eventually the classic sine
wave) that has been widely taught. Electrocardiographic
changes may be absent in hyperkalemia.
52 Life-threatening
hyperkalemia ([6.5 mmol L
-1) can slow atrioventricular
conduction or cause asystole, ventricular tachycardia,
ventricular ﬁbrillation, and PEA. Several congenital or
acquired conditions, including burns and upper/lower
motor neuron lesions, can cause upregulation of nicotinic
acetylcholine receptors and cardiac arrest via a massive
release of potassium, especially when intravenous succi-
nylcholine is used to facilitate intubation.
53 The prevalence
of hyperkalemia as a cause of cardiac arrest in hospitalized
patients is sufﬁciently high that it should be included in the
differential diagnosis of every patient with a new wide-
complex arrhythmia. Its treatment has been widely
described in the literature.
49
Malignant hyperthermia
Malignant hyperthermia is a rare but potentially fatal
manifestation of hypermetabolism which is triggered by
exposure to speciﬁc drugs in susceptible individuals. The
hallmark of this rare syndrome is a sudden and rapid
increase of uncompensated oxygen consumption in indi-
viduals exposed to succinylcholine and volatile inhalation
agents, including enﬂurane, halothane, isoﬂurane, sevoﬂu-
rane, and desﬂurane. Inherited genetic mutations of the
sarcoplasmic reticulum can result in massive release of
intracellular calcium after exposure to a triggering
agent.
54-56 Clinical features of malignant hyperthermia
include unexplained tachycardia with hypertension, rapid
increase in end-tidal CO2 without hypoventilation,
increased minute ventilation if the patient is breathing
spontaneously, uncompensated or mixed metabolic
Table 4 Treatment of anaphylaxis
Pre-Arrest
• Stop or remove the inciting agent or drug (e.g., intravenous contrast
or latex)
• If feasible, stop surgery or procedure
• Oxygen at FIO2 of 1.0; intubate immediately for respiratory distress
• Epinephrine 0.5-3 lg kg
-1; start epinephrine infusion
(5-15 lg min
-1) for a goal SBP 90 mmHg; observe for myocardial
ischemia
• Watch for auto-PEEP if severe bronchospasm
• ± Vasopressin 2 U iv
• Intravenous ﬂuids/large bore access
• H1 blocker (diphenhydramine 50 mg iv)
• H2 blocker (famotidine 20 mg iv)
• ± Corticosteroid (e.g., 50-150 mg hydrocortisone iv)
• A tryptase level in the blood can be used to support the diagnosis
48
Cardiac Arrest
• CPR if no carotid pulse detected for 10 sec
• Epinephrine 1 mg iv, can repeat every 3-5 min or follow by
vasopressin 40 U
• Disconnect the ventilator brieﬂy if auto-PEEP suspected
• Consider tension pneumothorax if arrest preceded by severe
bronchospasm
• Add adjunctive therapies listed in pre-arrest
FIO2 = fraction of inspired oxygen concentration; SBP = systolic
blood pressure; PEEP = positive end-expiratory pressure; CPR =
cardiopulmonary resuscitation
Table 5 Treatment of gas embolism
Pre-Arrest
• Administer 100% oxygen and intubate for signiﬁcant respiratory
distress or refractory hypoxemia. Oxygen may reduce bubble size
by increasing the gradient for nitrogen to diffuse out
• Promptly place patient in Trendelenburg (head down) position and
rotate toward the left lateral decubitus position. This maneuver
helps trap air in the apex of the ventricle, prevents its ejection into
the pulmonary arterial system, and maintains right ventricular
output
• Maintain systemic arterial pressure with ﬂuid resuscitation and
vasopressors/beta-adrenergic agents if necessary. See the algorithm
for RV failure
• Consider transfer to a hyperbaric chamber if immediately available.
Potential beneﬁts of this therapy include compression of existing
air bubbles, establishment of a high diffusion gradient to speed
dissolution of existing bubbles, improved oxygenation of ischemic
tissues, and lowered intracranial pressure
Cardiac Arrest
• Circulatory collapse should be addressed with CPR, and
consideration should be given to more invasive procedures as
described above
• Early use of TEE to rule out other treatable causes of pulmonary
embolism
• Consider the right ventricular shock algorithm
RV = right ventricular; CPR = cardiopulmonary resuscitation;
TEE = transesophageal echocardiography
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123acidosis (lactic) with increased PaCO2, a rapid or delayed
(up to a few hours) increase in temperature, hyperkalemia
from rhabdomyolysis with severe dysrhythmias, myoglo-
binuria, disseminated intravascular coagulation (DIC) and
‘‘nonsurgical’’ bleeding, localized masseter muscle or
generalized muscle rigidity, and massive increase of plasma
creatine kinase. A clinician-based diagnosis of DIC sub-
stantially increases the risk of cardiac arrest and death.
57
The differential diagnosis for malignant hyperthermia
includes sepsis, thyrotoxicosis, pheochromocytoma, iatro-
genic warming, CO2 rebreathing, and neuroleptic malignant
syndrome.
Mortality from malignant hyperthermia was as high as
70% before the widespread awareness of this complication,
its early recognition, and its timely treatment with intra-
venous dantrolene.
54 The mortality from malignant
hyperthermia has decreased, and a recent study of patients
in the United States reports a mortality rate of 11.7%.
58
Malignant hyperthermia with cardiac arrest carries a mor-
tality of 50% in healthy young individuals under
anesthesia.
57 The most effective way to prevent malignant
hyperthermia is to avoid use of triggering agents in patients
suspected or known to be susceptible.
55
A treatment protocol for malignant hyperthermia is
given in Table 6.
Complications of central venous access
In the category of equipment-related damaging events, the
ASA Closed Claims Project found that central venous
placement is the most frequent event associated with death
and permanent brain damage during anesthesia.
7 Although
a pneumothorax is a well-described and relatively rare
complication of central venous catheter placement or
removal, an analysis from the ASA closed-claims database
suggests that hemothorax and tamponade are also impor-
tant though sometimes unrecognized fatal complications of
patients who undergo attempts at central venous cannula-
tion.
58,59 If a patient’s hemodynamic situation deteriorates
following central venous catheter placement, expeditious
focused echocardiography should be considered in addition
to chest radiography.
60
Part 2
Introduction
When ACLS was ﬁrst introduced, it was the consensus
product of a multidisciplinary group with a common
interest in ACLS. At the time, there was little scientiﬁc
Table 6 Treatment of malignant hyperthermia
• Discontinue all anesthetic and switch from the anesthesia ventilator to manual Ambu bag ventilation from a separate source of oxygen. Switch
to a dedicated clean anesthesia ventilator or transport or ICU ventilator when feasible. Continue ETCO2 monitoring if feasible
• Stop surgery when feasible
• Switch to intravenous anesthetic if necessary
• Sodium dantrolene (be sure you know where it is in your hospital and how to prepare it): give 2.5 mg kg
-1 or 1 mg lb
-1 initial dose. Repeat
bolus of Na dantrolene, titrating to tachycardia and hypercarbia (10 mg kg
-1 suggested upper limit, but more may be given as needed, up to
30 mg kg
-1)
• Begin active cooling: ice packs to groin, axilla, and neck; cold intravenous solutions into the peritoneal cavity when feasible; nasogastric or
peritoneal lavage when feasible
• Stop cooling measures at 38 C to avoid overshooting
• If hyperkalemia suspected by peaked ECG T waves or intraventricular conduction delay conﬁrmed by high K serum level: calcium chloride
10 mg kg
-1, insulin 0.1 U kg
-1 ? 50 mL D50w for adult or 1 mL kg
-1 for pediatrics. Repeat as necessary
• Metabolic acidosis: 100 mEq of HCO3
- in adults, then titrate to pH 7.2. Normalize pH if conﬁrmed rhabdomyolysis (suggested threshold, CPK
10,000 IU L
-1)
• Respiratory acidosis: treatment is controversial due to adverse hemodynamic effects of hyperventilation if low-ﬂow state is conﬁrmed. (We
suggest an initial goal of modest permissive hypercarbia with a goal ETCO2 of 50-60 mmHg)
• Dysrhythmias: avoid calcium antagonists after Na dantrolene, potential for worsening hyperkalemia
• Myoglobinuria with oliguria: place Foley catheter; increase rate of ﬂuid resuscitation
• Invasive pressure monitoring when feasible, more HCO3
- to neutralize urine pH, consider intravenous mannitol
• Supportive measures for disseminated intravascular coagulation (DIC)
• Call for help, including the MH hotline, if feasible (www.mhaus.org) call 1-800-644-9737 or 1-800-MH-HYPER in the USA and Canada;
outside the USA, call 00113144647079
• When the crisis is resolved: Consider caffeine-halothane muscle biopsy in vitro contracture test, molecular genetic testing for genetic mutation
analysis for patient’s relatives (sensitivity 25%)
Table adapted from http://www.mhaus.org/ website
ICU = intensive care unit; ETCO2 = end-tidal carbon dioxide; ECG = electrocardiogram; D50W = dextrose in water (50%); CPK = creatine
phosphokinase; MH = malignant hyperthermia
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123evidence to guide and shape the guidelines that the group
eventually authored. Fortunately, there was an interest in
scenarios that were sufﬁciently common to permit sys-
tematic study, which facilitated subsequent revisions of the
ACLS guidelines.
61 However, given that cardiac arrest
occurs rarely in the perioperative period, it is difﬁcult, or
impossible, to perform large epidemiological studies and
generate evidence-based guidelines.
Recent surveys among anesthesiologists suggest a lack
of awareness of both basic and anesthesia-related knowl-
edge regarding resuscitation from cardiac arrest.
62,63 One
recent study has documented delay in the cardioversion and
deﬁbrillation of patients with shockable rhythms in the
perioperative setting.
64 Despite these challenges, detailed
reviews of this topic are now available,
65 and there is a
wealth of expertise and experience among anesthesiolo-
gists in managing both circulatory crisis and cardiac arrest
in perioperative patients.
After performing a review of the relevant literature, we
offer these suggestions, hoping that they will inspire sys-
tematic studies and more formal guidelines to manage
these rare perioperative events.
Pre-cardiac arrest issues
Rescuing a patient from an intraoperative crisis requires
two separate and very distinct components: comprehension
that the patient is in crisis and effective action.
66-68 Some
clinicians may not recognize the early signs and symptoms
of physiological deterioration that often precede adverse
events.
66 Failure to rescue may be a misidentiﬁed ‘‘cause’’
of cardiac arrest. Regrettably, in some instances, failure to
rescue is really the inability to rescue a patient from an
underlying process that becomes so severe (after delayed
recognition of a crisis in evolution) that an adverse event,
including death, is inevitable despite the timely institution
of maximal support.
66,69
Escalating care
In addition to initiating therapies during crisis, it is also
appropriate to consider escalating the level of monitoring to
correspond with the level of supportive care. Clinicians
should assess the patient’s known comorbidities, surgical
logistics, hemodynamic effects of the anesthetics used, and
ongoing autonomic nervous system modulation (e.g.,
tachydysrhythmias with hypotension vs bradydysrhythmias
with hypotension). The timely insertion of both an arterial
catheter and a central venous catheter will likely be very
helpful in the serial evaluation and management of patients
(outlined below).
70 Insertion of invasive monitors should
not take precedence over supportive measures. The decision
to escalate the level of monitoring, similar to the decision to
escalate therapies, is ultimately a clinical decision that
considers a large number of patient and surgical factors and
is beyond the scope of these recommendations.
Left ventricular failure
The management of left ventricular (LV) failure is sub-
stantially different from the management of RV failure. In
both settings, an adequate circulating volume is essential
for ventricular ﬁlling and forward ﬂow. The failing LV is
best supported with afterload reduction when possible,
followed by the administration of positive inotropic
agents.
71,72 Mechanical assist devices are available in some
settings to support the patient with LV failure, but esca-
lation of therapy to that level may not always be possible or
clinically appropriate (Fig. 1).
Right ventricular failure
The failing RV is best managed with a combination of
pulmonary vasodilators and positive inotropic agents.
Unlike the setting of LV failure that may require afterload
reduction, the use of systemic arterial vasoconstrictors for
RV dysfunction may improve end-organ perfusion and
cardiac output (Fig. 2).
73,74 At present, mechanical assist
devices are not used to manage the vast majority of patients
with RV failure. With the exception of patients with
infarction of the RV, the following most common causes of
an RV-limited circulation share the pathophysiology of
elevated pulmonary vascular resistance: severe obstructive
lung disease (including chronic obstructive pulmonary
disease [COPD] and chronic bronchitis), obstructive sleep
apnea with sleep-disordered breathing, morbid obesity,
massive pulmonary embolism, recurrent thromboembo-
lism, primary pulmonary hypertension, and pulmonary
hypertension from inﬂammatory destruction of pulmonary
capillaries (e.g., systemic sclerosis).
73
Clinical progression to shock
Some patients will continue to deteriorate despite volume
infusions. In these cases, anesthesiologists may administer
small boluses of vasopressor drugs or initiate inotropic
support.
If therapy with catecholamines does not improve
hemodynamics, small boluses of vasopressin (arginine
vasopressin [AVP] 0.5-2 U iv) may work where other cat-
echolamines have failed. Extensive literature documents the
use of AVP and its analogs in low-ﬂow states, cardiopul-
monary arrest, and general and regional anesthesia.
75-78
Given the autonomic imbalance of the perioperative period,
consideration should be given to the use of atropine in any
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123patient who does not manifest the anticipated tachycardic
response in a crisis.
79
If the patient’s clinical condition continues to deterio-
rate, several immediate diagnostic and corrective measures
should be considered, including focused echocardiography
and, if feasible, reduction of anesthetics (Table 7).
80-82
Ventilation during severe shock or cardiac arrest
Practitioners may be concerned that reducing ventilation in
a patient in shock or in severe respiratory failure will have
deleterious effects. Although this has been the conventional
wisdom in anesthesia and medicine, studies from the
past 15 years suggest a survival beneﬁt from moderate
hypoventilation and respiratory acidosis. For example,
hypoventilation is associated with a lower incidence of
barotrauma in patients with acute respiratory distress syn-
drome (ARDS) or COPD and is rarely a cause of
hypoxemia. Patients with severe lung disease can tolerate
hypercarbia and respiratory acidosis.
83-88
Hyperventilation is deleterious in all conditions of low-
ﬂow state. Studies of ventilation during shock emphasize
the following principle: In a low-ﬂow state, the duration of
increased intrathoracic pressure is proportional to the
ventilation rate, tidal volume, inspiratory time, and delayed
chest decompression and is inversely proportional to cor-
onary and cerebral artery perfusion.
84,89-91 For example,
ventilation at 20 breaths min
-1 during CPR is associated
with signiﬁcantly lower survival than ventilation at 10
breaths min
-1. The most recent ACLS guidelines empha-
size avoiding hyperventilation during CPR until an
advanced airway device (endotracheal tube, laryngeal mask
airway device, or esophageal airway) is inserted. This can
be achieved via a higher compression:ventilation ratio
(30:2) for single-rescuer CPR for victims of all ages
(except newborns) and for two-rescuer CPR for adult vic-
tims. Once an advanced airway is in place, the respiratory
rate should be maintained at no more than 10 breath-
s min
-1 with an inspiratory time of one second and the
tidal volume limited to ‘‘chest rise’’ (approximately
500 mL in an average 70 kg adult).
3 Capnography is usu-
ally a more reliable indicator of ROSC than carotid or
femoral arterial pulse palpation.
3 If rescuers are concerned
that the capnograph is malfunctioning, blowing into the
sidestream CO2 collecting tube is a quick way to assess
this.
New technologies and devices providing automatic
CPR
92,93 and an airway in-line negative inspiratory valve
Fig. 1 Treatment algorithm of
left ventricular failure with
cardiogenic shock.
SPV = systolic pressure
variation; SVR = systemic
vascular resistance in
dyne sec
-1 cm
5 m
2;
PTX = pneumothorax;
IABP = intraortic balloon
pump; VAD = ventricular
assist device; PEEP = positive
end-expiratory pressure;
ACEi = angiotensin-converting
enzyme inhibitor
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123providing increased venous return during chest decom-
pression
94 have all been associated with an increased rate
of ROSC, although no clear increase in hospital discharges
has been observed.
Auto-positive end-expiratory pressure
Auto-positive end-expiratory pressure (auto-PEEP), also
known as intrinsic PEEP or gas trapping, is a well-
described cause of circulatory collapse and may be difﬁcult
to recognize as a cause of PEA/electromechanical disso-
ciation.
95 It occurs almost exclusively in patients with
obstructive lung disease, including asthma and COPD
(emphysema), and is exacerbated by hyperventilation. In
these patients, patterns of ventilation that do not allow
sufﬁcient time for complete exhalation produce a gradual
increase in the end-expiratory volume and pressure in the
lung. This pressure is transmitted to the great veins in
the thorax, which depresses both venous return and
cardiac output. As auto-PEEP increases, venous return
declines.
96,97 Auto-positive end-expiratory pressure should
be considered a cause of rapid hemodynamic deterioration
in an anesthetized patient with acute bronchospasm.
Detecting and decreasing auto-PEEP is a straightfor-
ward way to support a sagging circulation. In Fig. 3, the
failure of the expiratory ﬂow waveforms to return to zero
Fig. 2 Treatment algorithm of right ventricular failure with cardio-
genic shock. iNO = inhaled nitric oxide
Table 7 Corrective measures for clinical progression to shock and a
modiﬁed stepwise approach for cardiac arrest in the operating room based
on the American Heart Association’s 2010 ACLS Guidelines and the 2008
International Liaison Committee on Resuscitation Consensus Statement on
post-cardiac arrest syndrome
Corrective Measures for Clinical Progression to Shock
• Recognize a true crisis
• Call for help
• Call for deﬁbrillator
• Hold surgery and anesthetic if feasible
• Administer FIO2 of 1.0
• Conﬁrm airway positioning and functioning
• Assess oxygen source and anesthetic circuit integrity
• Review ETCO2 trends before hemodynamic instability
Generate a Differential Diagnosis
• Evaluate procedure and consult with procedural colleagues
• Review recently administered medications
• Obtain chest radiograph to rule out tension pneumothorax if airway
resistance acutely increased
• Obtain echocardiogram (transesophageal echocardiogram if patient’s
trachea is intubated or if patient has a surgically prepped chest) to
evaluate ventricular ﬁlling, ventricular function, and valvular function,
and to exclude pericardial tamponade (Focused Echocardiographic
Evaluation and Resuscitation [FEER] exam
80)
• Empiric replacement therapy with corticosteroids (in patients who have
not been previously treated with steroids, hydrocortisone 50 mg iv and
ﬂudrocortisone 50 lg po/nasogastric is an appropriate dose
81,82)
Perioperative Cardiac Arrest
Circulation • Check pulse for 10 sec
• Effective two-rescuer CPR:
1. Minimize interruptions
2. Chest compression rate 100 compressions min
-1
3. Depth 2 in, full decompression, real-time feedback.
4. Titrate CPR to A-line BP diastolic 40 mmHg or ETCO2
20 mmHg
• Drug Rx
• Attempt CVL placement
Airway • Bag mask ventilation until intubation
• Endotracheal intubation
• Difﬁcult airway algorithm
Breathing • Respiratory rate 10 breaths min
-1
• VT to visible chest rise
• TI 1 sec
• Consider inspiratory threshold valve (ITV)
Deﬁbrillation • Deﬁbrillation if shockable rhythm
• Repeat deﬁbrillation every 2 min if shockable rhythm
Post Cardiac Arrest
• Invasive monitoring
• Final surgical anesthetic plan
• Transfer to ICU
ACLS = advanced cardiac life support; BLS = basic life support;
CPR = cardiopulmonary resuscitation; FIO2 = fraction of inspired oxy-
gen concentration; ETCO2 = end-tidal carbon dioxide; BP = blood
pressure; CVL = central venous line; VT = tidal volume; TI = inspira-
tory time; ICU = intensive care unit
594 V. K. Moitra et al.
123baseline before the next inspiration is indicative of the
presence of auto-PEEP. In the absence of a ﬂow waveform
display, auto-PEEP should be ruled out by temporarily
disconnecting the endotracheal tube and observing the
‘‘step-up’’ gain of invasive or noninvasive systolic blood
pressure. A ROSC upon discontinuance of all resuscitative
maneuvers, described as the Lazarus phenomenon, is most
likely the consequence of sudden termination of extreme
dynamic hyperinﬂation during CPR, particularly when
hyperventilation is applied.
98
If auto-PEEP is suspected as the cause of circulatory
crisis, disconnecting a patient’s tracheal tube from the
ventilator for a brief time (5-10 sec) can produce a dra-
matic improvement in the circulation. Patients who
demonstrate dramatic improvement in response to this
maneuver will beneﬁt from maximal therapy for obstruc-
tion/bronchospasm and will likely fare best with a reduced
respiratory rate, short inspiratory time (to promote a longer
expiratory time), and lower tidal volumes (no more than
8m L  kg
-1).
Hypovolemia and systolic and pulse pressure variation
Hypovolemia is a common cause of perioperative hypo-
tension. Reliable indicators of ﬂuid responsiveness (an
increase in stroke volume with ﬂuid administration) in
patients receiving tidal volumes of at least 8 mL kg
-1
include systolic and pulse pressure variation and stroke
volume variation.
99,100 The greater the ﬂuctuation of the
systolic pressure and pulse pressure of an arterial catheter
tracing with mechanical ventilation, the more likely the
patient will respond (increase cardiac output) to volume
infusion (Fig. 4). Plethmysography may show a similar
large respiratory variation.
101-103 Unfortunately, the pul-
satile part of the signal is diminished in the presence of low
cardiac output or increased systemic vascular resistance.
104
Elevations in pulse pressure and systolic pressure variation
may not always suggest ﬂuid responsiveness in a few but
important clinical circumstances, including RV shock and
all causes of obstructive shock (e.g., auto-PEEP, cardiac
tamponade, tension pneumothorax, pulmonary hyperten-
sion, and abdominal compartment syndrome).
90,105
The corollary is also true: Minimal or absent systolic
and pulse pressure variation with respiration strongly
suggests that interventions, other than the infusion of vol-
ume or increasing venous return via vasopressors, will be
required to support the circulation (e.g., adding positive
inotrope agents or eliminating negative inotrope agents).
Importantly, excessive tidal volumes ([10 mL kg
-1),
increased residual volume and lung compliance (emphy-
sema), and decreased chest wall compliance (3rd degree
chest burn, obesity, prone position) will also cause an
increase in systolic pressure variation requiring practitio-
ners to make incremental adjustments to their criteria for
volume responsiveness.
99 Additional indices of ﬂuid
responsiveness include the passive leg raise (a quick,
reversible, and easy to perform maneuver in which the
patient’s legs are raised and a change in blood pressure is
assessed—useful in spontaneously ventilating patients),
variation in inferior vena cava diameter with respiration via
ultrasonography (if access to the abdomen is possible), and
esophageal Doppler assessment of aortic velocity.
100,106-112
In the setting of severe hypotension, it is reasonable for
practitioners to provide volume resuscitation, as long as
there is an increase in blood pressure and/or cardiac output
without an increased requirement of FIO2 or worsening of
Fig. 3 Auto-PEEP during mechanical ventilation. Failure of the
expiratory waveforms to return to zero baseline before the next
inspiration is indicative of the presence of auto-PEEP. PEEP =
positive end-expiratory pressure
Fig. 4 Analytical description of respiratory changes in arterial
pressure during mechanical ventilation. The systolic pressure and
the pulse pressure (systolic minus diastolic pressure) are maximum
(SPmax and PPmax, respectively) during inspiration and minimum
(SPmin and PPmin, respectively) a few heartbeats later, i.e., during
the expiratory period. The systolic pressure variation (SPV) is the
difference between SPmax and SPmin. The assessment of a reference
systolic pressure (SPref) during an end-expiratory pause allows the
discrimination between the inspiratory increase (Dup) and the
expiratory decrease (Ddown) in systolic pressure. Pa = arterial
pressure; Paw = airway pressure. (This ﬁgure is reproduced with
permission from the publisher. Michard F: Changes in arterial
pressure during mechanical ventilation. Anesthesiology 2005; 103:
419-28)
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123total lung compliance (both possible signs of cardiogenic
pulmonary edema).
Rescue sequence for cardiac arrest in the operating
room
For a variety of reasons, recognizing the time to commence
CPR in the OR is more difﬁcult than it may appear to
outsiders. First, false alarms vastly outnumber real events
because disconnection of sensors (‘‘asystole’’), blood
draws, and electrocautery are more common than cardiac
arrest in most ORs.
113,114 Monitoring devices can also fail
from heavy use. Second, hypotension and bradycardia are
relatively common occurrences in the OR, and most
patients recover to an adequate hemodynamic status with
minimal intervention. Third, it can be difﬁcult or impos-
sible to obtain satisfactory monitoring in many patients,
especially those with vasculopathy, hypothermia, burns,
vasoconstriction, or morbid obesity.
115
The features of cardiac arrest in the OR include ECG
with pulseless rhythm (ventricular tachycardia [V-tach],
ventricular ﬁbrillation [V-ﬁb], severe bradycardia, and
asystole), loss of carotid pulse[ten seconds, loss of end-
tidal CO2 with loss of plethysmograph, and/or loss of
arterial line tracing. Once cardiac arrest is conﬁrmed,
effective CPR should be initiated immediately in the OR.
More important, the rescuer should provide physiological
feedback and monitor the data from the ECG, pulse
Fig. 5 Intubation. Algorithm
for managing the airway and
producing the least possible
disruption in chest
compressions DL = direct
laryngoscopy;
LMAD = laryngeal mask
airway device;
ETT = endotracheal tube
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123oximetry, end-tidal CO2 (ETCO2), CVP, and arterial cath-
eter. Effective chest compression is indicated by an ETCO2
close to or above 20 mmHg. In 100% of cases, an
ETCO2\10 mmHg after 20 min of standard ACLS is
associated with failure of ROSC.
116-119 A relaxation (dia-
stolic) pressure (calculated at the time of full chest
decompression) of 30-40 mmHg in the presence of an
arterial catheter has been associated with a higher rate of
ROSC, even after prolonged CPR.
120-122 Feedback on the
quality of chest compressions can be provided by some of
the new deﬁbrillators.
123
Table 8 Amnemonic approach to the differential diagnosis of bra-
dycardia and nonshockable cardiac arrest
Hypoxia Toxins (anaphylaxis/anesthesia)
Hypovolemia Tension pneumothorax
Hyper-/Hypokalemia Thrombosis/Embolus, pulmonary
Hydrogen ion (acidemia) Thrombosis coronary
Hypothermia Tamponade
Hypoglycemia Trauma (hemorrhagic shock, CV injury)
Malignant Hyperthermia qT prolongation
Hypervagal Pulmonary hyperTension
CV = cardiovascular
Fig. 6 Bradycardia. With
information from the ACLS
algorithm for bradycardia.
ACLS = advanced cardiac life
support; CVL = central venous
line or catheter; ETCO2 = end-
tidal carbon dioxide
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123In the presence of a CVP, the estimate of coronary
perfusion pressure (CPP) during CPR is more accurate than
by aortic relaxation only. Coronary perfusion pressure can
be estimated by brieﬂy freezing the monitoring screen with
the arterial line and synchronizing the CVP waveforms.
Coronary perfusion pressure is calculated at the time of full
chest decompression and is equal to the arterial catheter
pressure minus CVP. A CPP[15 mmHg is associated
with an increased rate of ROSC.
124,125
Table 7 shows a stepwise therapeutic approach to car-
diac arrest in the OR which is based on the 2010 American
Heart Association ACLS sequence and the International
Liaison Committee on Resuscitation consensus statement
on post-cardiac arrest syndrome.
126 An algorithm for
Table 9 Pharmacological approach to shockable rhythm post deﬁ-
brillation and recommended infusion doses
Rhythm 1st Line 2nd Line 3rd Line
Ventricular tachycardia *Amiodarone
Lidocaine
Procainamide
Ventricular ﬁbrillation Amiodarone
Torsades de pointes
kMagnesium
* Amiodarone: 300 mg iv bolus, then 150 mg iv bolus. Repeat every
5 min up to 1.5 g total. Infusion rate: 1 mg min
-1
 Lidocaine: Load 1.0-1.5 mg kg
-1 bolus. Repeat 0.5-0.75 mg kg
-1
3-5 minlater.Maximumdose3 mg kg
-1.Infusionrange:1-4 mg min
-1
 Procainamide: 20-50 mg min
-1 iv. Maximum: 17 mg kg
-1. Infu-
sion rate: 1-4 mg min
-1
k Magnesium sulfate: 2 g iv for torsades de pointes, hypomagnese-
mia, or hypokalemia. May repeat three times
Fig. 7 Tachycardia. With
information from the ACLS
algorithm for tachycardia.
ACLS = advanced cardiac life
support;
TEE = transesophageal
echocardiography;
MH = malignant hyperthermia;
EF = ejection fraction;
MAT = multifocal atrial
tachycardia; EAT = ectopic
atrial tachycardia;
SVT = supraventricular
tachycardia;
AF ? WPW = atrial
ﬁbrillation and Wolff-
Parkinson-White syndrome
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123coordinating airway management with CPR is shown in
Fig. 5.
ACLS operating room algorithms
Symptomatic bradycardia evolving to nonshockable arrest
Sixteen causes (8H and 8T) of perioperative bradycardia
and nonshockable cardiac arrest (asystole and PEA) are
listed in Table 8 as an extension of the current ‘‘6H and
6T’’-based American Heart Association algorithm.
3 Bra-
dycardia and hypotension caused or precipitated by
vagotonic analgesics, physical manipulations that increase
vagal tone, and sympatholysis from anesthetic agents and
regional/neuraxial anesthetic techniques require immediate
evaluation and intervention.
The different spectrum of causes of bradycardia makes it
reasonable to attempt earlier pacing in this patient popu-
lation than in most other settings. Failure to intervene in a
timely fashion can allow the patient to deteriorate into a
nonshockable cardiac arrest. However, there is no evidence
to suggest any advantage from the use of pacing (which
may delay chest compressions) when full cardiac arrest is
in progress.
127-130 Typical indications for emergency pac-
ing include hemodynamically symptomatic bradycardia
unresponsive to positive chronotropic agents, regardless of
the cause; symptomatic tissue conduction dysfunction of
the sinus node; Mobitz type II second degree and third
Fig. 8 Comprehensive
algorithm. With information
from the ACLS comprehensive
algorithm. Rescuers are
prompted to evaluate or
empirically treat early for
hyperkalemia.
Echocardiography is especially
useful in establishing the most
likely cause of pulseless
electrical activity and focusing
resuscitation efforts.
ACLS = advanced cardiac life
support
Perioperative ACLS 599
123degree block; alternating bundle branch block; or bifas-
cicular block.
3 A treatment sequence approach to per-
ioperative bradycardia is given in Fig. 6.
Symptomatic tachycardia evolving to pulseless shockable
arrest (ventricular tachycardia, ventricular ﬁbrillation,
and torsades de pointes)
Although symptomatic tachycardia, often triggered by
severe hypovolemia or an imbalance between surgical
stimulus and anesthetic depth, is frequent in the perioper-
ative arena, data regarding its incidence and management
are lacking.
131 The differential diagnosis for nonshockable
tachycardia includes the 8Hs and 8Ts.
Evolution to a malignant rhythm is unlikely in the
absence of severe cardiac comorbidities and/or anesthesia
complications. Persistent hemodynamic instability with
tachycardia can sometimes degenerate rapidly to symp-
tomatic bradycardia. Immediate cardioversion is indicated
for a patient with hemodynamic instability from tachy-
cardia (ventricular rate[150 beats min
-1).
3 Cardiac
pacing may be necessary in patients after cardioversion
because some patients’ rhythms will convert to symptom-
atic bradycardia. Overdrive pacing of supraventricular or
ventricular tachycardia refractory to drugs or electrical
cardioversion is also appropriate in perioperative
patients.
132
In Table 9 and Figs. 7 and 8, there are lists of practical
considerations for the management of symptomatic tachy-
cardia in the perioperative period.
Conclusion
Cardiac arrest in the perioperative setting is rare and has a
different spectrum of causes that compel situation-speciﬁc
adaptations of ACLS algorithms. In fact, there are intuitive
differences in patient management when the health care
provider has prior knowledge of a patient’s medical his-
tory, is immediately aware of the probable cause of arrest,
and initiates medical management within seconds. Since it
is both uncommon and heterogeneous, perioperative car-
diac arrest has not been described or studied to the same
extent as cardiac arrest in the community; thus, recom-
mendations for management must be predicated on expert
opinion and physiological understanding rather than on the
standards currently being used in the generation of ACLS
protocols in the community.
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